PHASTAR attends reception to recognise 2019 Queen’s Award

PHASTAR's Kevin Kane and Andrew MacGarvey speaking with Princess Beatrice at the award ceremony

PHASTAR have attended a reception at Buckingham Palace for winners of the 2019 Queen’s Award for Enterprise. The company was awarded for excellence in the International Trade category following exponential growth from a one-person operation in 2007, to a global CRO with offices in four continents within the space of one decade. Around 300 people attended the event, representing the various businesses that won the Queen’s Award for International Trade,Innovation, Sustainable Development, and Promoting Opportunity. The Queen’s Award, now in its 53rd year, focuses on outstanding achievement by UK businesses, with winning companies invited to a royal reception in Buckingham Palace and receiving an official grant of appointment from one of The Queen’s representatives. 

The event was hosted by Prince Charles and other members of the royal family. PHASTAR was represented by Kevin Kane (CEO) and Andrew MacGarvey (MD), who met Princess Beatrice and Kelly Tolhurst, a sitting MP and Minister for Small Business, Consumers and Corporate Responsibility. PHASTAR’s reputation as a quality provider of statistics, programming and data science services to the pharmaceutical and biotechnology industries now sees it as one of the top 10 data focused CROs worldwide. 

Continue Reading

Highlights from PHASTAR's Life Science Reception

On Thursday, June 13th, PHASTAR hosted its first Life Science Reception in Cambridge, MA, at the Royal Sonesta hotel. Representatives from a number of leading pharmaceutical and biotech companies were in attendance.

After opening remarks from Founder and CEO Kevin Kane and Managing Director Andrew MacGarvey, Paul Stark, the Director of PHASTAR’s Boston/Cambridge office launched the evening’s technical program with a thoughtful discussion of the benefits and risks of planning interim looks at clinical trial data; that is, assessing trial outcomes before the trial is fully completed.  Whether framed in a Bayesian or a classical frequentist approach, this exciting branch of adaptive trial design can dramatically reduce the duration and number of subjects required to conduct a trial but requires expert design to optimize its advantages, avoid critical pitfalls, and ensure regulatory acceptance.

Continue Reading

Announcing the opening of PHASTAR’s European hub in Berlin

PHASTAR office Berlin

Beer, bratwurst, biostats! PHASTAR is delighted to announce the opening of its European hub in Berlin, Germany. The opening of this office marks an important milestone in PHASTAR’s decade long journey – as well as being our 10th office, the Berlin office allows PHASTAR closer access to our mainland European customers, and to retain a foothold in the European market, futureproofing our award-winning service offering in the range of possible post-Brexit environment.

As part of PHASTAR’s ambitious growth plans, a huge importance has been placed on opening in new locations worldwide. We will continue focusing on attracting highly qualified, experienced staff, expanding our footprint to meet the needs of our ever-growing customer base. PHASTAR is committed to garnering new relationships with big pharma and smaller biotechs as well as further diversifying our business.

Continue Reading

Data Visualisation: customised graphics and combining outputs

It has become easier to produce customised graphics in SAS and to produce reports that combine outputs from several different procedures. This means that refined outputs can be produced that allow more targeted monitoring of individual patients and populations of patients.

Customised Graphics

There is now a range of graphical elements that allow graphs in SAS to easily convey a range of information for the user to see several concepts at one time all in one picture.

Continue Reading

PHASTAR's approach to Risk-Based Monitoring

Data quality and integrity are key aspects of Good Clinical Practice (GCP) and sponsors are expected by regulators to demonstrate oversight of clinical studies to ensure proper conduct, safety of study subjects and accuracy and completeness of the clinical study data. Risk Based Monitoring is an approach that aims to implement improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting, while continuing to ensure human subject protection and reliability of trial results.

Oversight of a clinical study has traditionally included on-site data monitoring and performing Source Data Verification (SDV), i.e. confirming that the data in the CRF accurately reflects the source notes. 

Continue Reading